Article
Safety and immunogenicity of ChAd63-KH vaccine in post kala azar dermal leishmaniasis patients in Sudan
2020-09-01
Abstract excerpt
Post kala azar dermal leishmaniasis (PKDL) is a chronic, stigmatising skin condition occurring frequently after apparent clinical cure from visceral leishmaniasis. Given an urgent need for new treatments, we conducted a Phase IIa safety and immunogenicity trial of ChAd63-KH vaccine in Sudanese patients with persistent PKDL. LEISH2a ( NCT02894008 ) was an open label three-phase clinical trial involving sixteen adul...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 92b0d3b0-e3ca-59e2-be3f-36d028aa9771
- DOI
- 10.1101/2020.08.26.20180901
